Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (534)	5/8/2008 11:15:35 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

Quarterly report available here ir.targen.com I see that the enterprise value (as reported by Yahoo) is about minus half a million. As of March 31, 2008, our accumulated deficit totaled $303.6 million Here is the stuff TGEN highlighted for the quarter: In April 2008, the Company announced encouraging results from a Phase 1/2 clinical study demonstrating that treatment of three young adults with Leber's congenital amaurosis (LCA) with an AAV vector containing the RPE 65 coding sequence resulted in improved visual function in one patient. The study, titled "Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis," by Bainbridge, et al., conducted in collaboration with University College London and Moorfields Hospital, will appear in the May 22, 2008 issue of the New England Journal of Medicine. -- In April 2008, preclinical data characterizing the novel use of AAV vectors to deliver small interfering RNA (siRNA) for the treatment of Huntington's disease were published in the April 15th issue of Proceedings of the National Academy of Sciences of the United States of America. -- In April 2008, the Company acquired full exclusive rights to its preclinical Huntington's disease program from Sirna Therapeutics, a wholly owned subsidiary of Merck & Co., Inc. and former collaborator on the program. Sirna also assigned to Targeted Genetics a licensing agreement it has with the University of Iowa that covers certain IP related to RNA interference (RNAi) including AAV expressed RNAi. -- In March 2008, the Company announced that dosing has been completed for the Phase 1/2 clinical trial of tgAAC94 for the treatment of inflammatory arthritis. The Company plans to report additional Phase 1/2 results during 2008 at the American Society of Gene Therapy (ASGT), the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) in May, June and October respectively.